Statement of Principles concerning psoriatic arthritis (Reasonable Hypothesis) (No. 15 of 2021)

This instrument is a Statement of Principles (No. 15 of 2021) made by the Repatriation Medical Authority under subsection 196B(2) of the Veterans' Entitlements Act 1986, and it sets the medical and causal rules used to determine whether psoriatic arthritis, or death from psoriatic arthritis, can be connected to a person’s relevant service for the purposes of claims under the VEA and the Military Rehabilitation and Compensation Act 2004 (MRCA) (see s3 and s5). Mechanically, it replaces the earlier Statement of Principles concerning psoriatic arthropathy (No. 5 of 2012) by explicit repeal (s4). The instrument is dated 24 December 2020 and commenced on 25 January 2021 (ss1-2 and front matter).

Functionally, the Statement does three linked things. First, it defines the kind of disease covered, adopting a textual medical definition of psoriatic arthritis as a “seronegative chronic inflammatory arthritis, occurring in association with skin or nail psoriasis” (s7(2)). It notes the relevant ICD-10-AM codes (M07.0-M07.3) but states that the statutory meaning for the Statement is that given in s7(2) (ss7(3)-(4)). Second, it lists the specific factors that must exist, at minimum, to raise a reasonable hypothesis that the condition or death is related to relevant service; at least one factor in s9 must be present. Third, it sets rules about how those factors must relate to service: factors must be related to the person’s relevant service (s10(1)), and certain factors (s9(4)-(5)) apply only to material contribution or aggravation where the condition pre‑existed or was suffered before or during but did not arise out of service (s10(2)). The Schedule provides operative definitions used across the instrument, including “biologic agent”, “trauma to the affected joint”, “terminal event”, and the range of “relevant service” (Schedule 1).

The instrument records the Authority’s view that there is “sound medical‑scientific evidence” indicating that the condition and death from it can be related to relevant service (s8). That statement is the Authority’s stated evidentiary basis for adopting the factors in s9. The Statement is to be applied to claims to which section 120A of the VEA or section 338 of the MRCA apply (s5). The instrument does not itself create criminal penalties, administrative sanctions, or new statutory entitlements; it is a determinative evidential instrument used in applying the existing claims provisions of the VEA and MRCA. The text also provides cross‑reference mechanics where a factor in s9 refers to an injury or disease that is the subject of another Statement of Principles (s11).

The instrument’s principal legal mechanism is the “reasonable hypothesis” test implemented by a finite list of factors. The text requires that at least one of the listed factors in section 9 be present before it can be said that a reasonable hypothesis has been raised connecting psoriatic arthritis or death from psoriatic arthritis with the circumstances of a person’s relevant service (s9). The factors are concrete and limited: having psoriasis at the time of clinical onset (s9(1)); trauma to the affected joint within 30 days before clinical onset (s9(2)); taking a biologic agent for specified purposes for at least seven days before clinical onset (s9(3)); taking a biologic agent for at least seven days before clinical worsening (s9(4)); and inability to obtain appropriate clinical management for psoriatic arthritis (s9(5)).

Core definitional choices constrain application. The Statement defines “psoriatic arthritis” substantively as a seronegative chronic inflammatory arthritis occurring in association with skin or nail psoriasis (s7(2)), and it expressly makes that textual definition authoritative for the instrument, notwithstanding the ICD-10-AM coding reference (s7(3)). Death from psoriatic arthritis is taken to include death from a terminal event or condition that was contributed to by the person’s psoriatic arthritis (s7(5)). The Schedule defines “terminal event” with a non‑exhaustive list (pneumonia, respiratory failure, cardiac arrest, circulatory failure, cessation of brain function) and defines “biologic agent” and “trauma to the affected joint” with specific objective features (Schedule 1).

Two structural constraints shape causal attribution. First, section 10(1) requires that any factor relied upon must be related to the person’s relevant service, and Schedule 1 provides a list of what counts as relevant service for these purposes (operational, peacekeeping, hazardous, British nuclear test defence service under the VEA; warlike and non‑warlike service under the MRCA). Second, section 10(2) limits the application of s9(4)-(5) to situations of material contribution or aggravation where the person’s psoriatic arthritis was suffered or contracted before or during (but did not arise out of) the person’s relevant service. That is, biologic agent‑related worsening and inability to obtain appropriate clinical management are only grounds for material contribution or aggravation in a particular timing and causal posture.

The instrument also governs interactions with other Statements of Principles. If a factor in s9 refers to an injury or disease that is the subject of another Statement made under subsection 196B(2) of the VEA, then that other Statement’s factors apply according to its terms as in force from time to time (s11). That cross‑reference mechanism means claim adjudicators must consult other SOPs when a listed factor implicates another recognised condition.

The document applies to any claim to which section 120A of the Veterans’ Entitlements Act 1986 or section 338 of the Military Rehabilitation and Compensation Act 2004 applies (s5). The relevant individuals in practice are therefore people making such claims who have psoriatic arthritis or have died from psoriatic arthritis, and whose claim is to be assessed under the VEA or the MRCA claims provisions referenced. The Authority’s s8 statement frames the population as veterans, members of Peacekeeping Forces, or members of the Forces under the VEA, or members under the MRCA. Schedule 1’s definition of “relevant service” further particulars the categories: operational service, peacekeeping service, hazardous service, British nuclear test defence service under the VEA, and warlike or non‑warlike service under the MRCA (Schedule 1).

Practical actors affected by the Statement include medical practitioners and clinical record‑keepers who will be asked for evidence bearing on the factors in s9, and decision‑makers within the Department and any tribunal or reviewer that applies the Statements in claim determinations under the VEA and MRCA. The instrument’s factors create evidentiary expectations for medical opinions and records: for example, proof of psoriasis at clinical onset (s9(1)), contemporaneous documentation of trauma to the affected joint within 30 days before onset meeting the Schedule’s criteria, medication records showing biologic agent use for at least seven days before onset or clinical worsening (s9(3)-(4)), or documentation evidencing an inability to obtain appropriate clinical management (s9(5)).

The Statement also affects how other Statements of Principles interface with psoriatic arthritis claims. Where a factor in s9 refers to an injury or disease that is the subject of a different Statement, the rules of that other Statement apply as in force from time to time (s11). That creates an administrative dependence: claimants and advisers must identify and obtain evidence under any implicated Statements as well as under this instrument. The instrument does not create new payment entitlements itself. It functions as a determinative evidentiary framework used in adjudicating entitlement under VEA/MRCA provisions; those broader Acts set eligibility, benefits and procedural rules outside the instrument itself.

Finally, clinicians, hospitals and pharmaceutical record‑holders who maintain medication and treatment records are indirectly affected because the presence or absence of their records will be central to satisfying the conditions in s9. The Schedule’s definitions constrain how evidence is to be interpreted; for example, the Schedule’s detailed definition of “trauma to the affected joint” sets temporal and clinical thresholds that medical records must meet to be counted as establishing that factor.

The instrument does not create autonomous statutory duties or penalties; it establishes the criteria that must be met to raise a reasonable hypothesis connecting psoriatic arthritis or death from it with relevant service for the purposes of VEA and MRCA claims (s3, s5). The primary operational duty it imposes is on decision‑makers applying the VEA and MRCA: they must treat the factors in section 9 as the minimum list from which a reasonable hypothesis may be raised (s9). In practice that means an adjudicator must look for the existence of at least one of the factors in s9 and verify that the factor is related to relevant service as required by s10(1).

For claimants and their advisers, the instrument effectively creates a right to have claims assessed against the stated factors. That is, claimants can rely on the presence of one or more of the s9 factors plus a linking relationship to relevant service (s10) as the legal threshold for the reasonable hypothesis stage of claims processed under the sections of the VEA and MRCA identified in s5. Where a s9 factor refers to another Statement of Principles, claimants have the right to have the relevant other Statement applied according to its terms (s11).

The instrument creates precise evidential boundaries that structure required proof. Examples include:

• A claimant who seeks to rely on s9(1) must show that they had psoriasis at the time of the clinical onset of psoriatic arthritis (s9(1) read with s7(2)); the text places the emphasis on contemporaneous existence of psoriasis at clinical onset rather than on general history alone.

• A claimant seeking to rely on s9(2) must demonstrate a qualifying “trauma to the affected joint” within 30 days before clinical onset; the Schedule defines the shape of that trauma including 24‑hour onset of pain/tenderness/altered range and persistence for at least seven days unless specific medical interventions occur (Schedule 1).

• A claimant relying on s9(3) or s9(4) must show biologic agent use for at least seven days before clinical onset or before clinical worsening respectively, and the Schedule defines “biologic agent” and gives examples (Schedule 1).

• A claimant relying on s9(5) must demonstrate “inability to obtain appropriate clinical management for psoriatic arthritis”; the instrument provides no further definition of what constitutes “appropriate clinical management”, though s10(2) limits when s9(5) can be used to prove material contribution or aggravation.

The Statement of Principles text contains no express penalties, fines, sanctions, or enforcement provisions. It is an evidentiary instrument made under subsection 196B(2) of the VEA (s3) and applies to claims to which specified sections of the VEA and MRCA apply (s5). The instrument’s function is to set the factors that must exist for a reasonable hypothesis to be raised linking psoriatic arthritis or death from it with relevant service. It does not itself state enforcement mechanisms or administrative penalties for non‑compliance.

Enforcement in the practical sense is therefore procedural and embedded within the VEA and MRCA claims frameworks rather than contained in this instrument. Decision‑makers applying the VEA or MRCA must use this Statement to determine whether the required factual threshold (reasonable hypothesis) has been met, but the instrument does not enumerate sanctions for false claims, nor does it describe investigatory powers or obligations to produce evidence. The Schedule and the substantive sections do define terms and factual thresholds that guide how evidence is to be assessed: for example, the Schedule specifies temporal and clinical criteria for what constitutes qualifying trauma to the affected joint, thereby constraining how adjudicators should treat evidence of a traumatic event (Schedule 1).

Because the instrument cross‑references other Statements of Principles (s11), enforcement of issues that implicate those other Statements may be influenced by the content and standing of those Statements as in force from time to time, but this instrument itself does not prescribe enforcement modalities. Any penalties, administrative sanctions, review rights, or remedies remain matters governed by the VEA, the MRCA or other enactments and administrative rules; this Statement supplies medical‑causal criteria for the adjudication process.

In short, the Statement is not an enforcement statute; it is a determinative evidential framework that adjudicators must apply in claims processing, and the consequences of application or non‑application will flow through the statutory claim and review processes established by the VEA and MRCA rather than within the instrument itself.

The instrument is made under subsection 196B(2) of the Veterans’ Entitlements Act 1986 and expressly applies to claims to which section 120A of the VEA or section 338 of the MRCA applies (s3, s5). It therefore functions as a subordinate, statutory specification of medical and causal factors used within the statutory scheme set out by those Acts. The Statement does not amend those Acts; instead it provides the Authority’s determination, under the statutory power, of the factors that will be used in applying the relevant provisions of the VEA and MRCA.

Where a factor in section 9 refers to an injury or disease that is the subject of another Statement of Principles made under subsection 196B(2) of the VEA, this instrument instructs that the factors in that other Statement apply in accordance with its terms as in force from time to time (s11). That creates an explicit legal interaction: decision‑makers must identify and apply the contemporaneous terms of other Statements where cross‑references arise. The instrument therefore operates within a network of Statements; it is not standalone where interlocking conditions are implicated.

The instrument also references, but does not rely upon, ICD‑10‑AM coding. Section 7(3) and (4) note that while psoriatic arthritis attracts ICD‑10‑AM codes M07.0 to M07.3, for the purposes of this Statement the meaning is that given in subsection 7(2), and that a reference to an ICD‑10‑AM code is a reference to the particular edition specified. This means ICD codes might be used as ancillary identification but the textual definition in s7(2) governs interpretation under the Statement.

The Schedule defines terms that are also names of other statutes, for example MRCA and VEA (Schedule 1); those definitions are for the purposes of application of this instrument and do not alter those Acts. The Statement does not purport to displace statutory provisions in the VEA or MRCA concerning procedural matters, benefits, review rights, or other eligibility criteria. Rather, it supplies the medical causation criteria that those Acts call on the Repatriation Medical Authority to determine.

Finally, because the instrument is framed as operative for claims under particular sections of the VEA and MRCA, any remedial, review, appeal or enforcement processes established under those Acts will govern disputes about the application of the Statement. The instrument itself contains no separate conflict‑of‑laws provision; interactions with other laws are effected by reference and cross‑application of Statements as described in s11.

The instrument records its own commencement and its replacement of a prior Statement. It is titled The Statement of Principles concerning psoriatic arthritis (Reasonable Hypothesis) (No. 15 of 2021) and is dated 24 December 2020, with commencement on 25 January 2021 (ss1-2 and front matter). Section 4 expressly repeals The Statement of Principles concerning psoriatic arthropathy No. 5 of 2012 (Federal Register of Legislation No. F2012L00009) that had been made under subsection 196B(2) of the VEA. That is the sole repeal or supersession recorded in the instrument.

There are no further amendment entries in the text provided. The Schedule provides definitions that form part of the operative instrument at the date of commencement. The instrument also notes that where factors refer to an injury or disease that is the subject of another Statement of Principles, those other Statements apply “as in force from time to time” (s11). That language, while not an amendment history for this instrument, signals that this Statement is intended to operate in a dynamic statutory environment in which other SOPs may be updated; the instrument does not itself list subsequent amendments or variations.

The instrument’s front matter indicates formal execution by the Authority, with the Common Seal affixed at the direction of the Chairperson, Professor Nicholas Saunders AO. The text does not identify any subsequent variations, nor does it record legislative amendments post‑commencement. If and when another Statement replaces this instrument, or this instrument is otherwise amended, the source text here would need to be consulted for later repeal or amendment entries. As of the text provided, the recorded amendment history is limited to repeal of the 2012 Statement and commencement details for No. 15 of 2021.

The instrument itself contains no references to litigation, court decisions, tribunal determinations, or judicial consideration. It does not cite cases or judicial interpretations. The text does not record any prior adjudications about its terms or about the medical points it asserts. Consequently, within the bounds of the instrument as supplied, there is no litigation history to report.

Users seeking litigation history about the application of this Statement in particular claim determinations, reviews, or appeals will need to consult tribunal or court records and decisions arising after its commencement. The instrument’s s11 cross‑reference to other Statements of Principles could mean that litigation touching on related Statements might be relevant in future disputes, but such litigation is not recited in this instrument. The Authority’s statement in s8 that “there is sound medical‑scientific evidence” is an evidentiary assertion made by the Authority in support of the Statement; the instrument does not reproduce that evidence nor does it identify any judicial treatment of that evidence.

In summary, no litigation history is included or referenced in the instrument text. Any litigation concerning the interpretation or application of these provisions would be external to the instrument and must be sourced from judicial or tribunal records rather than from this Statement itself.

The instrument contains a number of textual features that can produce narrowly consequential interpretive issues. These are points that advisers and decision‑makers should note because the wording materially constrains when a factor will count for the reasonable hypothesis threshold.

1. Textual definition trumps coding. Section 7(2) gives the operative definition of psoriatic arthritis for the Statement as a seronegative chronic inflammatory arthritis occurring in association with skin or nail psoriasis, and s7(3) expressly states that for applying the Statement the meaning is that given in s7(2), notwithstanding the ICD‑10‑AM codes mentioned in s7(3)-(4). That means adjudicators must apply the textual definition rather than rely solely on ICD coding. In practice this can matter where records use ICD codes but do not describe the association with skin or nail psoriasis required by s7(2).

2. Timing and persistence thresholds for trauma are stringent. The Schedule’s definition of “trauma to the affected joint” requires a discrete event applying significant physical force, leading to damage, development of symptoms within 24 hours, and persistence of those symptoms for at least seven days unless specific medical interventions occurred (Schedule 1). The definition also accounts for cases where unconsciousness or analgesia masks symptoms, requiring that the signs appear on return to consciousness or withdrawal of analgesics. These temporal and clinical thresholds are precise, and failure to meet them on the facts will defeat reliance on s9(2).

3. Narrow temporal windows for trauma factor. Section 9(2) requires trauma within 30 days before clinical onset of psoriatic arthritis. Two distinct temporal requirements therefore must be satisfied: the Schedule’s 24‑hour symptom onset/persistence criteria plus the 30‑day proximity to clinical onset. Both must be documented to trigger s9(2).

4. Biologic agent timing. Sections 9(3)-(4) require use of a biologic agent for at least seven days before clinical onset or before clinical worsening respectively. The Schedule defines “biologic agent” broadly and gives examples, but the instrument requires a minimum seven‑day exposure prior to the relevant clinical event. Shorter exposures will not, on the face of the instrument, qualify.

5. Ambiguity in “clinical onset” and “clinical worsening”. The instrument uses the terms “clinical onset” and “clinical worsening” but does not define them. Those undefined terms may give rise to interpretive disputes about when the relevant clinical event occurred. Adjudicators will need to rely on clinical records and expert opinion to fix these moments. The instrument’s lack of definition is a source of evidential uncertainty.

This Statement is an evidentiary instrument. Compliance for claimants, their advisers, and clinicians consists principally of assembling and presenting the documentation and expert opinions that establish the presence of at least one factor in s9 and the required relationship to relevant service under s10.

Practical steps, grounded in the instrument’s text, are:

1. Establish the diagnosis using the Statement’s definition. Ensure clinical records explicitly address the textual definition in s7(2): that the condition is a seronegative chronic inflammatory arthritis occurring in association with skin or nail psoriasis. Do not rely solely on ICD‑10‑AM codes, because s7(3) states that the meaning of psoriatic arthritis for the Statement is the s7(2) textual definition. Clinical notes should identify skin or nail psoriasis in temporal relation to the arthritis onset.

2. For a psoriasis‑at‑onset claim under s9(1), obtain contemporaneous dermatological records indicating the presence of skin or nail psoriasis at the time of the clinical onset of psoriatic arthritis. The instrument requires simply “having psoriasis at the time of the clinical onset”; documentary evidence that ties the two temporally will be decisive.

3. For trauma claims under s9(2), document the discrete traumatic event and meet the Schedule’s elements. Records should show: the nature of the event involving significant physical force; medical evidence of damage to the joint; onset of symptoms within 24 hours of the event; and persistence of symptoms for at least seven days following their onset, unless one of the Schedule exceptions applies (immobilisation, intra‑articular injection, or surgery). If unconsciousness or analgesia masked symptoms, records should document return of signs on regaining consciousness or withdrawal of analgesia. Also ensure the trauma occurred within 30 days before the clinical onset of psoriatic arthritis (s9(2)).

4. For biologic agent factors under s9(3)-(4), obtain medication records and treating clinician statements showing the specific biologic agent, indication (treatment of cancer and autoimmune disease per s9(3)-(4)), dates of commencement and duration of use, and timing relative to clinical onset or clinical worsening. The instrument requires at least seven days of use before the relevant clinical event. The Schedule gives examples of biologic agents; clinicians’ notes should identify the agent and the clinical rationale for its use.

5. For inability to obtain appropriate clinical management under s9(5), assemble contemporaneous evidence of access problems, referrals, wait times, service limitations, or other documentation showing inability to obtain appropriate treatment. Because the Statement does not define “appropriate clinical management”, provide clinical opinions that link the absence or inadequacy of care to material contribution or aggravation, taking into account s10(2) which limits application of s9(5) to pre‑existing or pre‑service conditions in particular causal settings.